Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Darolutamide blocks the use of androgens by the tumor cells. Prednisone is used to lessen inflammation a

Trial Details

NCT ID

NCT06173362

Phase

PHASE2

Sponsor

University of California, Davis

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Abiraterone
Biospecimen Collection
Darolutamide
Prednisone

Locations (sample)

Sacramento, California, United States|38.58157,-121.4944

Key Eligibility Criteria

Ability to understand and willingness to sign an informed consent form
Histologically confirmed prostate adenocarcinoma
Advanced prostate cancer appropriate for treatment with abiraterone acetate plus prednisone or darolutamide as assessed by the treating physician
Participants are encouraged to be currently treated with androgen deprivation therapy (ADT) or having undergone bilateral orchiectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →